Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Zhang, Cheng; Zhong, Jiang; Stucky, Andres; Chen, Xue-Lian; Press, Michael; Zhang, Xi
• Is Part Of: Clinical epigenetics. Volume 7:Issue 1(2015)
• Page Start: 1
• Page End: 10
• Publication Date: 2015-12
• Subjects: Histone acetylation -- Acute lymphoblastic leukemia -- Histone acetyltransferase -- Histone deacetylase -- Biomarker -- Clinical application; Epigenesis -- Periodicals; Genetic regulation -- Periodicals; Human cytogenetics -- Periodicals; Human molecular genetics -- Periodicals; Cancer -- Genetic aspects -- Periodicals; 611.01816
• DOI: 10.1186/s13148-015-0151-8
• Languages: English
• ISSNs: 1868-7075

Abstract

Abstract Acute lymphoblastic leukemia (ALL) has been generally considered a genetic disease (disorder) with an aggressive tumor entity of highly proliferative malignant lymphoid cells. However, in recent years, significant advances have been made in the elucidation of the ALL-associated processes. Thus, we understand that histone acetylation is involved in the permanent changes of gene expression controlling ALL developmental outcomes. In this article, we will focus on histone acetylation associated with ALL, their implications as biomarkers for prognostic, and their preclinical and clinical applications.